Urgent

Surfactant replacement therapy in the newborn – indications & administration

Exogenous surfactant · Paediatric
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Exogenous surfactant replaces deficient endogenous surfactant, most often in preterm respiratory distress syndrome, improving compliance and oxygenation and reducing air leaks and mortality. It may be given prophylactically, as early rescue, or via minimally invasive techniques to avoid intubation.

Red flags

  • Sudden desaturation/bradycardia during instillation
  • Blocked or displaced ETT with surfactant reflux
  • Pulmonary haemorrhage after administration
  • Rapid lung compliance change causing over-inflation/air leak
  • Failure to respond suggesting alternative diagnosis

Assessment

Differential diagnosis

  • Respiratory distress syndrome (surfactant deficiency)
  • Transient tachypnoea of the newborn (does not need surfactant)
  • Meconium aspiration syndrome with surfactant inactivation
  • Congenital pneumonia/sepsis
  • Pulmonary haemorrhage
  • Congenital surfactant protein deficiency

Investigations

  • Chest radiograph (ground-glass, air bronchograms for RDS)
  • Arterial blood gas and FiO2 requirement
  • Pre-/post-ductal SpO2
  • Confirm correct ETT position before instillation
  • CRP and blood culture if infection possible
  • Blood glucose

Management

  • Identify candidates: preterm RDS with escalating oxygen/support needs, or other surfactant-inactivating disease with respiratory failure.
  • Favour early rescue over routine prophylaxis; treat when CPAP is failing (e.g. FiO2 threshold ~0.30 in a baby on CPAP with RDS).
  • Choose technique: minimally invasive surfactant administration (LISA/MIST) via thin catheter in spontaneously breathing infants on CPAP, or via ETT (INSURE or ongoing ventilation).
  • Prepare: warm the surfactant per manufacturer instructions, confirm airway, and have monitoring and resuscitation equipment ready.
  • Consider premedication/analgesia balanced against the desire to preserve respiratory drive for LISA.
  • Instil the dose (often as a single aliquot or divided) and ensure distribution; for LISA keep the baby breathing on CPAP.
  • Monitor closely for transient desaturation, bradycardia or reflux of surfactant and adjust ventilation.
  • After ETT administration, if using INSURE, extubate promptly to CPAP once stable.
  • Reduce FiO2 and ventilator pressures as lung compliance improves to avoid hyperoxia and air leak.
  • Watch for pulmonary haemorrhage from a newly significant PDA shunt after surfactant.
  • Consider a repeat dose for ongoing or recurrent high oxygen/support requirement.
  • Document response and continue supportive neonatal care.

Drugs & doses

Poractant alfa 100–200 mg/kg intratracheal initial dose (200 mg/kg for rescue), repeat 100 mg/kg every 6–12 h as needed
Beractant 100 mg/kg (4 mL/kg) intratracheal, repeated up to total of 4 doses in 48 h
Atropine 20 microgram/kg IV premedication to reduce bradycardia (if premedicating)
Fentanyl 1–2 microgram/kg IV for analgesia if intubating for INSURE (avoid heavy sedation in LISA)

Disposition

NICU with ventilation/CPAP capability; senior neonatal supervision for LISA/INSURE; monitor response and escalate support as needed.

Complications & pitfalls

  • Transient hypoxia and bradycardia during dosing
  • Pulmonary haemorrhage (especially with a large PDA)
  • Pneumothorax from rapid compliance change if pressures not reduced
  • Surfactant reflux/airway obstruction
  • Reintubation after failed LISA/INSURE

Exam pearls

  • Early rescue surfactant plus CPAP is preferred over routine intubation for prophylaxis in most settings.
  • LISA/MIST reduces need for mechanical ventilation and BPD in spontaneously breathing preterms.
  • Reduce ventilator pressures and FiO2 quickly after dosing as compliance improves.
  • A sudden PDA shunt can precipitate pulmonary haemorrhage after surfactant.
  • Surfactant also benefits MAS and some pneumonias by overcoming inactivation.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.